Royalty Pharma to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

Rhea-AI Summary

Royalty Pharma plc (Nasdaq: RPRX) will present at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022, at 2:20 p.m. ET. Interested parties can access the live webcast from Royalty Pharma's Events page, with an archive available for at least 30 days. The company is renowned for being the largest buyer of biopharmaceutical royalties and a key innovator funder, boasting a diverse portfolio of royalties linked to over 35 commercial products including notable therapies like Imbruvica and Xtandi.

NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the Goldman Sachs 43^rd Annual Global Healthcare Conference on June 14, 2022 at 2:20 p.m. ET.

The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events. The webcast will also be archived for a minimum of thirty days.

About Royalty Pharma

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on around 35 commercial products, including AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Johnson & Johnson’s Tremfya, Gilead’s Trodelvy, Merck & Co.’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates. For more information, visit www.royaltypharma.com.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6772
ir@royaltypharma.com

FAQ

When is Royalty Pharma's presentation at the Goldman Sachs Healthcare Conference?

Royalty Pharma is scheduled to present on June 14, 2022, at 2:20 p.m. ET.

Where can I watch Royalty Pharma's presentation webcast?

The webcast will be accessible from Royalty Pharma's Events page on their website.

How long will the webcast of Royalty Pharma's presentation be available?

The webcast will be archived for a minimum of 30 days.

What is Royalty Pharma known for?

Royalty Pharma is the largest buyer of biopharmaceutical royalties and a significant funder of innovation in the biopharmaceutical industry.

What products are included in Royalty Pharma's portfolio?

Royalty Pharma's portfolio includes royalties on around 35 commercial products like Imbruvica, Xtandi, and Tysabri.